“…Some of them, such as aglycon, are usually inactive, but amongst hundreds of anthracyclines molecular analogues with antitumoral and antimicrobial activity, FDA approved a small number for clinical administration: actinomycin D (dactinomycin), daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin, valrubicin, enediyne, guanorycin, etc. (Saeidnia, 2015). Some of these are active, especially after chemical change, irrespective of cell cycle stage, even in G0, inhibiting proliferation, acting as pro-apoptosis and anti-epithelial-mesenchymal transition factors, thus inhibiting metastasis (Zhou J, 2013).…”